Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;20(3):e202201059.
doi: 10.1002/cbdv.202201059. Epub 2023 Feb 9.

Furo[2,3-d]pyrimidines as Mackinazolinone/Isaindigotone Analogs: Synthesis, Modification, Antitumor Activity, and Molecular Docking Study

Buer Song  1   2 , Lifei Nie  1 , Khurshed Bozorov  1   3 , Chao Niu  1   2 , Rustamkhon Kuryazov  3   4 , Haji Akber Aisa  1   2 , Jiangyu Zhao  1   2
Affiliations

Furo[2,3-d]pyrimidines as Mackinazolinone/Isaindigotone Analogs: Synthesis, Modification, Antitumor Activity, and Molecular Docking Study

Buer Song et al. Chem Biodivers. 2023 Mar.

Abstract

The chemical transformation of the tricyclic furo[2,3-d]pyrimidines was performed under isosteric and scaffold-hopping strategies focusing on the synthesis of its arylidene and imine-containing derivatives. Naturally-occurring alkaloids mackinazolinone and isaindigotone were as templates of target heterocycles. Synthesized compounds evaluated for their antitumor activity on human cancer cervical HeLa, breast MCF-7, and colon HT-29 cell lines. Four compounds: 8c, 8e, 10b, and 10c demonstrated potency against HeLa and HT-29 cell lines, and IC50 values were between 7.37-13.72 μM, respectively. The molecular docking results showed that compounds 8c and 10b had good binding and high matching with the target EGFR protein.

Keywords: EGFR; antitumor activity; arylidene; furo[2,3-d]pyrimidine; mackinazolinone.

PubMed Disclaimer

References

    1. R. G. Stevens, G. C. Brainard, D. E. Blask, S. W. Lockley, M. E. Motta, ‘Breast cancer and circadian disruption from electric lighting in the modern world’, Ca-Cancer J. Clin. 2014, 64, 207-218.
    1. Y. Chi, D. Wang, J. Wang, W. Yu, J. Yang, ‘Long non-coding RNA in the pathogenesis of cancers’, Cells 2019, 8.
    1. D. Sia, A. Villanueva, S. L. Friedman, J. M. Llovet, ‘Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis’, Gastroenterology 2017, 152, 745-761.
    1. H. A. Burris, ‘Shortcomings of current therapies for non-small-cell lung cancer: Unmet medical needs’, Oncogene 2009, 28, S4-S13.
    1. M. Arnold, E. Morgan, H. Rumgay, A. Mafra, D. Singh, M. Laversanne, J. Vignat, J. R. Gralow, F. Cardoso, S. Siesling, I. Soerjomataram, ‘Current and future burden of breast cancer: Global statistics for 2020 and 2040’, Breast 2022, 66, 15-23.

LinkOut - more resources